NEW YORK, July 19, 2021 – Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $10.00 per share. The Company received total proceeds …
Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock
NEW YORK, July 15, 2021 – Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $10 per share. The gross proceeds of …
Immunic, Inc. Announces Proposed Public Offering of Common Stock
NEW YORK, July 14, 2021 – Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All the shares to be sold in the offering will …
Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist
– IMU-935 Has Been Observed In Vitro to Inhibit the Generation of Th17 Cells and Production of IL-17 Cytokines Without Impairing RORγt Function Required for Normal Thymocyte Development; May Avoid Risk of Lymphoma Formation Seen in Third-Party RORγt Programs – – Full Pharmacokinetic and Blinded Safety Data Set From the Completed Single-Ascending Dose Part of the Ongoing Phase 1 Clinical …
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
– Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo, Intended to Provide Straightforward Path to Regulatory Approval – – Supportive Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis (PMS), Designed to Corroborate IMU-838’s Neuroprotective Potential and Support Differentiated Profile – – Company Expects Initiation of Both ENSURE …
Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July
NEW YORK, June 28, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, industry and investor conferences in July: June 30-July 3: The International Federation of Psoriasis Association’s 6th World Psoriasis & Psoriatic Arthritis Conference 2021. Dr. Thomas …
Immunic, Inc. to Participate in Industry and Investor Conferences in June
NEW YORK, June 10, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in June: June 14-18: BIO Digital (formerly BIO International Convention). Members of the company’s business development team will host one-on-one partnering meetings …
Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
NEW YORK, June 1, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr. Singh will be responsible for legal and compliance matters and will become part of the management …
BEAT-COV Endorses Initiative of the German Government for EUR 300 Million Funding Program for Late-Stage COVID-19 Therapies (in German Only)
BEAT-COV begrüßt Initiative des Bundes für 300 Millionen Euro Förderprogramm für versorgungsnahe COVID-19-Medikamente BEAT-COV (Biotech Emergency Alliance for Therapies against COVID-19) Initiative wurde 2020 von den Biotechunternehmen AiCuris, Atriva, Immunic und InflaRx ins Leben gerufen BEAT-COV forderte frühzeitig staatliche Unterstützung in Höhe von 500 bis 750 Millionen Euro für die Förderung der Entwicklung und Verfügbarmachung von COVID-19-Medikamenten Deutschland, 17. Mai …
Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity
– EMPhASIS Cohort 2 Interim Analysis Confirmed 30 mg Dose of IMU-838 as Most Appropriate for Planned Phase 3 Program in Relapsing-Remitting Multiple Sclerosis, Expected to Begin in the Second Half of 2021 – – Secured Full Rights to IMU-838 with Settlement of Remaining Royalty Obligation to 4SC AG for $17.25 Million (50% in Cash and 50% in Shares of …